Home Cart Sign in  
Chemical Structure| 146535-11-7 Chemical Structure| 146535-11-7

Structure of Tyrphostin AG1296
CAS No.: 146535-11-7

Chemical Structure| 146535-11-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR. It also inhibits FGFR and c-Kit with IC50 of 12.3 μM and 1.8 μM in Swiss 3T3 cells.

Synonyms: AG 1296; AG1296

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tyrphostin AG1296

CAS No. :146535-11-7
Formula : C16H14N2O2
M.W : 266.29
SMILES Code : COC1=C(OC)C=C2N=CC(C3=CC=CC=C3)=NC2=C1
Synonyms :
AG 1296; AG1296
MDL No. :MFCD00270913
InChI Key :QNOXYUNHIGOWNY-UHFFFAOYSA-N
Pubchem ID :2049

Safety of Tyrphostin AG1296

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tyrphostin AG1296

RTK

Isoform Comparison

Biological Activity

Target
  • PDGFR

    PDGFR, IC50:0.3 μM-0.5 μM

  • FGFR

    FGFR (Swiss 3T3), IC50:12.3 μM

  • c-Kit

    c-Kit (Swiss 3T3), IC50:1.8 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat brain astrocytes (RBA-1 cells) 10 μM 1 hour Inhibited JEV-induced MMP-9 expression PMC3298505
Vascular smooth muscle cells 5 µM 15 min AG1296 inhibited PDGF-stimulated PDGFR-β phosphorylation but had no effect on Ang II-induced p70 PDGFR-β phosphorylation PMC1513282
IPSC-EC 20 μM, 10 μM, 5 μM 24 hours AG1296 significantly improved cell survival under serum withdrawal and enhanced angiogenesis. PMC8762958
Rat brain astrocytes (RBA-1) 0.1, 1, 10 μM 24 hours AG1296 significantly inhibited LPS-induced MMP-9 protein expression in a concentration-dependent manner PMC6982104
Rat lung myofibroblasts 100 μM 24 hours AG1296 specifically inhibited autophosphorylation of PDGF-R and blocked PDGF-stimulated [3H]thymidine uptake PMC1866660
Rat brain astrocytes (RBA-1) 10 μM 4 hours (mRNA expression) or 6 hours (promoter activity) AG1296 inhibited LPS-induced MMP-9 mRNA expression and promoter activity PMC6982104
A172 cells 5 μM 48 hours Inhibited PDGFR α activity, reducing the increase in GOLM1 mRNA and protein levels PMC5745991
Canine left atrial fibroblasts 10 μM 48 hours AG1296 reversed PDGF-AB-induced STAT3 phosphorylation and collagen secretion PMC5852635
Human lung fibroblasts (CCL-151) 10 μM 5-minute pretreatment Inhibited PDGFR kinase activity but did not attenuate stretch-induced ERK1/2 activation PMC2911572
Mouse mesangial cells 10 μM 60 minutes Inhibited morphine- and PDGF-BB-induced MAPK/ERK phosphorylation PMC3828056
Mouse mammary C127 cells 50 μM To investigate the effect of PDGF receptor tyrosine kinase inhibitor on VSOR Cl⁻ currents, results showed that AG1296 had no significant effect on VSOR Cl⁻ currents. PMC2343000
PAH SMC 10 μM, 20 μM AG1296 significantly suppressed the proliferation of PAH SMCs. PMC8762958

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Vanadium pentoxide-induced pulmonary fibrosis model Intraperitoneal injection 50 mg/kg Administered 1 hour before V2O5 instillation and again 2 days after instillation AG1296 was more than 90% effective in preventing the increase in hydroxyproline, significantly reducing pulmonary fibrosis PMC1866660
Rat Sugen/hypoxia-induced pulmonary hypertension model Subcutaneous injection 50 mg/kg/day Once daily for three weeks AG1296 significantly improved pulmonary arterial function, reduced right ventricular systolic pressure, and reversed occlusive changes in pulmonary arteries. PMC8762958
BALB/c mice Allergic rhinitis murine model Intraperitoneal injection 9 mg/kg 4 hours before each OVA inhalation, continued for 3 months To evaluate the preventive effects of AG1296 on nasal airway remodeling in an allergic rhinitis murine model. Results showed that AG1296 significantly reduced eosinophil infiltration, suppressed MMP-9/TIMP-1 expression, and prevented subepithelial fibrosis in the nasal mucosa. PMC3242059

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.76mL

0.75mL

0.38mL

18.78mL

3.76mL

1.88mL

37.55mL

7.51mL

3.76mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories